Acrivon Details ACR-525 JAK1 Data and EoE Phase 2 Plan at R&D Event
ACRV sits 26% above its 52-week low of $1.27 on light trading volume (0.3× avg).
Summary
Acrivon presented the first detailed data package on ACR-525, the oral JAK1 inhibitor it acquired on November 6, claiming 49x biochemical JAK1/JAK2 selectivity, clean Phase 1 healthy-volunteer results and a Phase 2-ready plan in eosinophilic esophagitis. The deck adds scientific substance to a four-day-old acquisition but no new timeline or spending guidance.
Key Events · Product Development and Regulatory · ACRV
-
ACR-525 Data Package Unveiled
Acrivon detailed ACR-525, the oral JAK1 inhibitor acquired from Aqilion on 2026-11-06, reporting 49x biochemical JAK1/JAK2 selectivity (JAK1 IC50 3.5 nM vs JAK2 171 nM) and >120x cellular selectivity.
-
Phase 1 Safety and PK Support Once-Daily Dosing
Phase 1 healthy-volunteer studies showed dose-proportional PK with T1/2 ~12h, a dose-dependent CXCL10 decrease, no SAEs and limited reticulocyte effect, consistent with minimal JAK2 inhibition.
-
EoE Chosen as First Indication
ACR-525 is Phase 2-ready in eosinophilic esophagitis, wholly-owned with no milestone or royalty obligations and composition-of-matter protection to 2038; the company did not state a Phase 2 start date.
-
Differentiation Claims vs Approved JAK Inhibitors
AP3 profiling indicates non-SMAD TGF-beta/STAT3 pS727 suppression (potential antifibrotic effect) and no pro-apoptotic BAD S134 phosphorylation, unlike brepocitinib and londamocitinib.
Analysis · ACRV · Life Sciences
Acrivon used a two-hour KOL webcast to put real data behind the ACR-525 asset it bought four days ago. The pitch is selectivity: ACR-525 is 49x selective for JAK1 over JAK2 biochemically (3.5 nM vs 171 nM) and more than 120x in cells, which the company argues could mean JAK1-driven efficacy with less JAK2-related toxicity. Phase 1 healthy-volunteer data showed dose-proportional exposure, a ~12-hour half-life supporting once-daily oral dosing, a dose-dependent drop in CXCL10, no serious adverse events and limited reticulocyte impact. Management also flagged non-SMAD TGF-beta/STAT3 suppression as a possible antifibrotic edge and the absence of pro-apoptotic BAD signaling as a safety differentiator versus brepocitinib and londamocitinib. The commercial case rests on EoE having no approved oral advanced small molecule — only injected dupilumab as a step-up biologic — in a US population the deck puts above 500,000. Nothing here changes the cash story: the last 10-Q showed $90.0M funding operations into Q4 2027, and the company gave no timeline for an EoE Phase 2 start, so the next hard datapoint is that trial, not this presentation.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACRV was trading at $1.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $67.3M. The 52-week trading range was $1.27 to $3.56. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.